Skip to main content

Table 1 Number of patients with B-level disease activity at study entry in each BILAG body system

From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

Body system Number of patients Contributing signs/symptoms* (number of patients)
I. General/constitutional 3 Fatigue/malaise/lethargy (3)
   Anorexia/nausea/vomiting (2)
   Unintentional weight loss > 5% (1)
II. Mucocutaneous 13 Malar erythema (11)
   Active localized discoid lesions (2)
   Mild maculopapular eruption (1)
III. Neurological 0  
IV. Musculoskeletal 2 Arthritis (2)
V. CV/Respiratory 2 Dyspnea (2)
   Pleuropericardial pain (2)
VI. Vasculitis 5 Minor cutaneous vasculitis (nailfold/digital vasculitis, purpura, urticaria) (5)
VII. Renal 0  
VIII. Hematology 1 Anemia (hemoglobin < 11 g/dL) (1)
  1. *Signs and symptoms that contributed to the B-level disease activity according to BILAG rules.